Alkermes Plc ALKS shares are trading higher by $14.33 at $57.81 in Friday's session. There are two catalysts that are factoring into the rally.
First of all, after the close on Thursday, the company announced positive data from a depression treatment trial. Also, the issue moved higher on positive comments from CNBC's Jim Cramer.
After a higher open, it continued in that direction until peaking at $59.40 and reversing course.
That level is shy of its January 20 high of $61.56. The following day the issue sank to $33.69 following the announcement that ALKS5461 study for depression disorder did not meet its endpoint.
The ensuing decline off the high has found intraday support at $54.80 and now the issue is attempting to remain at the $57 handle.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
